COST-EFFECTIVENESS OF IMATINIB AS ADJUVANT TREATMENT FOR RESECTED GASTROINTESTINAL STROMAL TUMORS (GIST) VERSUS BEST SUPPORTIVE CARE: CANADIAN PERSPECTIVE

被引：0
|
作者：
El Ouagari, K. [1 ]
Pawar, V [2 ]
Coombs, J. [3 ]
Rubin, J. [2 ]
机构：
[1] Novartis Pharmaceut Canada, Dorval, PQ, Canada
[2] I3 Innovus, Medford, MA USA
[3] Novartis, Florham Pk, NJ USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A270 / A270
页数：1
相关论文
共 50 条
  • [41] Long-term adjuvant treatment of gastrointestinal stromal tumors (GIST) with imatinib-a comment and reflection on the PERSIST-5 study
    Cameron, Silke
    TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY, 2018, 3
  • [42] Verification of imatiNib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE)
    Mabasa, V.
    Taylor, S. C.
    Chu, C. C.
    Moravan, V.
    Peacock, S.
    Knowling, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] Correction to: Cost-Effectiveness Analysis of Molnupiravir Versus Best Supportive Care for the Treatment of Outpatient COVID-19 in Adults in the US
    Hardik Goswami
    Adnan Alsumali
    Yiling Jiang
    Matthias Schindler
    Elizabeth R. Duke
    Joshua Cohen
    Andrew Briggs
    Amy Puenpatom
    PharmacoEconomics, 2023, 41 : 605 - 605
  • [44] Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study
    Zuidema, Sander
    Desar, Ingrid M. E.
    van Erp, Nielka P.
    Kievit, Wietske
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 85 (09) : 1994 - 2001
  • [45] COST-EFFECTIVENESS ANALYSIS OF SORAFENIB VERSUS BEST SUPPORTIVE CARE (BSC) IN ADVANCED HEPATOCELLULAR CARCINOMA (AHCC): THE PRIVATE HEALTH CARE SYSTEM PERSPECTIVE IN BRAZIL
    Muszbeck, N.
    Vioix, H.
    Munir, U.
    Schiola, A.
    Valderrama, A.
    Teich, V
    VALUE IN HEALTH, 2010, 13 (03) : A36 - A36
  • [46] CLINICAL BENEFIT AND ECONOMIC IMPACT OF THREE-YEARS OF ADJUVANT IMATINIB IN KIT plus GASTROINTESTINAL STROMAL TUMORS (GIST)
    Sanon, M.
    Parthan, A.
    Taylor, D. C.
    Coombs, J.
    Paolantonio, M.
    Sasane, M.
    VALUE IN HEALTH, 2012, 15 (04) : A212 - A212
  • [47] A COST-EFFECTIVENESS ANALYSIS OF ONABOTULINUMTOXINA VERSUS BEST SUPPORTIVE CARE (BSC) FOR THE TREATMENT OF ANTICHOLINERGIC TREATMENT-REFRACTORY NEUROGENIC DETRUSOR OVERACTIVITY (NDO)
    Hamid, R.
    Loveman, C.
    Millen, J.
    Colayco, D.
    Stanisic, S.
    Gultyaev, D.
    VALUE IN HEALTH, 2014, 17 (07) : A470 - A470
  • [48] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, Karissa
    Powell, Lauren C.
    Popoff, Evan
    L'Italien, Gil J.
    Pawinski, Robert
    Ahern, Aideen
    Large, Sam
    Tran, Thang
    Jenkins, Aaron
    JOURNAL OF MEDICAL ECONOMICS, 2024, 27 (01) : 627 - 643
  • [49] Cost-effectiveness of rimegepant oral lyophilisate compared to best supportive care for the acute treatment of migraine in the UK
    Johnston, K.
    Powell, L.
    Popoff, E.
    L'Italien, G.
    Pawinski, R.
    Ahern, A.
    Large, S.
    Tran, T.
    Jenkins, A.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [50] Cost-effectiveness of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health care perspective
    Aosta-Scharplatz, M.
    Beamer, B.
    Frial, T.
    Gandhi, S. K.
    VALUE IN HEALTH, 2007, 10 (06) : A221 - A221
12345